Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

Shuji Hiramoto, Tomoko Tamaki, Kengo Nagashima, Tetsuo Hori, Ayako Kikuchi, Akira Yoshioka, Akira Inoue

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background: Clinical efficacy of aggressive end-of-life (EOL) chemotherapy remains unclear. Method: Medical records of patients with advanced cancer between August 2011 and August 2016 were retrospectively analyzed. The primary endpoint was to identify prognostic factors at the last administration of chemotherapy. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details. Results: Among 300 evaluated patients, the number of patients who died within 14 and 30 days from the last administration of chemotherapy were 16 (5.3%) and 50 (16.7%), respectively. Multivariate analysis revealed that ECOG-PS (OR 3.698, p < 0.001) and GPS2 (OR 3.791, p = 0.028) were significant prognostic factors. The MST of patients with both PS 2–4 and GPS2 (+) was 38 days, while that in patients with both PS 0–1 and GPS2 (−) was 134.5 days. The prevalence rate of nausea and vomiting (25.0%) and the mean hydration volume (0.50 L/day) in patients who died within 30 days from the chemotherapy was significantly higher than others (7.4%) (0.20 L/day). Conclusion: ECOG-PS and GPS were significant prognostic factors for aggressive EOL chemotherapy. Information on these factors may aid clinical decision-making in terms of risk–benefit balance, particularly in patients with poor prognosis.

Original languageEnglish
Pages (from-to)454-459
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume24
Issue number4
DOIs
Publication statusPublished - 2019 Apr 15

Keywords

  • Chemotherapy
  • End-of-life
  • Glasgow Prognostic Score
  • Prognostic factor

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer'. Together they form a unique fingerprint.

Cite this